Suchergebnisse - "Verbinnen, Thierry"

PubPharm (11)

1

Simeprevir plus peginterferon/ribavirin for HCV genotype 1‐infected treatment‐naïve patients in China and South Korea

enthalten in: Journal of gastroenterology and hepatology | 2016

von Wei, L. | Han, T. | Yang, D. | +16

2

Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial

enthalten in: The lancet / Infectious diseases | 2015

von Reddy, K. | Zeuzem, S. | Zoulim, F. | +14

3

Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region

enthalten in: Antiviral research | 2015

von Sarrazin, C. | Lathouwers, E. | Peeters, M. | +11

4

Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies

enthalten in: Journal of hepatology | 2015

von De Meyer, S. | Verbinnen, T. | Fevery, B. | +8

5

Efficacy of Re-treatment With TMC435 as Combination Therapy in Hepatitis C Virus–Infected Patients Following TMC435 Monotherapy

enthalten in: Gastroenterology | 2012

von Lenz, O. | de Bruijne, J. | Vijgen, L. | +10

6

Replication capacity of minority variants in viral populations can affect the assessment of resistance in HCV chimeric replicon phenotyping assays

enthalten in: The journal of antimicrobial chemotherapy | 2012

von Verbinnen, T. | Jacobs, T. | Vijgen, L. | +4

7

Tracking the Evolution of Multiple In Vitro Hepatitis C Virus Replicon Variants under Protease Inhibitor Selection Pressure by 454 Deep Sequencing

enthalten in: Journal of virology | 2010

von Verbinnen, T. | Van Marck, H. | Vandenbroucke, I. | +7

8

In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435

enthalten in: Antimicrobial agents and chemotherapy | 2010

von Lenz, O. | Verbinnen, T. | Lin, T. | +16

9

In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor

enthalten in: Antimicrobial agents and chemotherapy | 2009

von Lin, T. | Lenz, O. | Fanning, G. | +12

10

Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors

enthalten in: Bioorganic & medicinal chemistry letters | 2007

von Raboisson, P. | Lenz, O. | Lin, T. | +7